as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹56.94
Change
-0.72 (-1.25%)
Open
₹58.23
Prev. Close
₹57.66
Day High
₹59.4
Day Low
₹55.93
Volume Analysis
Traded
2,532
Delivered
1,107
Delivery %
43.72%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (1)
- •Below-average fundamentals quality score (49/100)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹62.38 | ₹60.89 | ₹58.91 | ₹57.42 | ₹55.44 | ₹53.95 | ₹51.97 |
| Fibonacci | ₹60.89 | ₹59.56 | ₹58.75 | ₹57.42 | ₹56.09 | ₹55.28 | ₹53.95 |
| Camarilla | ₹57.89 | ₹57.58 | ₹57.26 | ₹57.42 | ₹56.62 | ₹56.3 | ₹55.99 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-18.56%
1 Week
+1.28%
1 Month
-3.77%
3 Months
-5.31%
6 Months
+28.13%
1 Year
-19.86%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Company Overview
Sector
Healthcare
Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.
TopFund Analysis
Krebs Biochemicals & Ind scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 49/100. The strongest factor is Corporate Governance (85/100), while Liquidity (23/100) is the weakest area to weigh before deciding. Notably: Below-average fundamentals quality score (49/100).
TopFund Score — Fundamentals Quality
49/100 — WeakData confidence: 58/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Corporate Governance
Institutional Ownership
Risk & Volatility
Liquidity
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Company has enclosed herewith copy of Newspaper Advertiesment of the Notice issued to shareholders wrt 34th AGM.
Krebs Biochemicals filed FY26 annual report and AGM notice for 29 Sep 2026, including RPT approval up to ₹120 crore.
Company has enclosed herewith copy of newspaper advertiesment w.r.t. prior intimation of 34th AGM of the Company.
Source: BSE regulatory filings, via Screener.in.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 26.76% | 26.77% | 26.75% | 26.75% | 26.76% | 26.76% | 26.75% | 26.76% | 26.76% | 26.76% | 26.77% | 26.76% |
| Promoters | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% |
| FII | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Krebs Biochemicals & Ind (this stock) | — | — | — | — |
| Sun Pharmaceutical Ind L | 444,405 | 35.2 | 5.32 | 16.0% |
| Divi S Laboratories Ltd | 255,487 | 85.8 | 15.25 | 16.5% |
| Torrent Pharmaceuticals L | 189,746 | 85.0 | 20.11 | 27.4% |
| Apollo Hospitals Enter. L | 128,055 | 60.9 | 13.51 | 21.2% |
| Zydus Lifesciences Ltd | 120,089 | 24.7 | 4.48 | 21.2% |
| Cipla Ltd | 111,060 | 31.0 | 3.23 | 11.6% |
Which Mutual Funds Hold Krebs Biochemicals & Ind?
Frequently Asked Questions about Krebs Biochemicals & Ind
Krebs Biochemicals & Ind (KREBSBIO) closed at ₹56.94 on NSE on 25 September 2026, down 0.72 (1.25%) from the previous close.
Krebs Biochemicals & Ind trades on the NSE (National Stock Exchange of India) under the symbol KREBSBIO.
Krebs Biochemicals & Ind has a TopFund Quality Score of 49/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Krebs Biochemicals & Ind?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.